Su, Qi https://orcid.org/0000-0001-9100-387X
Wong, Oscar W. H.
Lu, Wenqi
Wan, Yating
Zhang, Lin https://orcid.org/0000-0003-1634-3780
Xu, Wenye
Li, Moses K. T.
Liu, Chengyu
Cheung, Chun Pan
Ching, Jessica Y. L.
Cheong, Pui Kuan
Leung, Ting Fan https://orcid.org/0000-0002-6469-1926
Chan, Sandra
Leung, Patrick
Chan, Francis K. L.
Ng, Siew C. https://orcid.org/0000-0002-6850-4454
Funding for this research was provided by:
This study is supported by InnoHK, The Government of Hong Kong, Special Administrative Region of the People’s Republic of China, and The D.H. Chen Foundation.
Article History
Received: 1 August 2023
Accepted: 20 May 2024
First Online: 8 July 2024
Change Date: 4 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41564-024-01900-w
Competing interests
: F.K.L.C. is a Board Member of CUHK Medical Centre. He is a co-founder, non-executive Board Chairman, honorary Chief Medical Officer and shareholder of GenieBiome Ltd. He receives patent royalties through his affiliated institutions. He has received fees as an advisor and honoraria as a speaker for Eisai Co. Ltd., AstraZeneca, Pfizer Inc., Takeda Pharmaceutical Co., and Takeda (China) Holdings Co. Ltd. S.C.N. has served as an advisory board member for Pfizer, Ferring, Janssen, and Abbvie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie, and Takeda. She has received research grants through her affiliated institutions from Olympus, Ferring, and Abbvie, and is a scientific co-founder and shareholder of GenieBiome Ltd. She also receives patent royalties through her affiliated institutions. Q.S., L.Z., Y.W., F.K.L.C. and S.C.N. are named inventors of patent applications (no. 63/533,871, US, 2023) held by the CUHK and MagIC that cover the therapeutic and diagnostic use of microbiome. The remaining authors declare no competing interests.